XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
X4 Pharmaceuticals, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.75+0.16 (+6.18%)
Close on Oct 19, 2026
- Market cap
- $347.45M
- P/E (TTM)
- –
- Dividend yield
- –
X4 Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $272.65M | $164.85M |
| Enterprise Value | $64.65M | $87.06M |
| PS Ratio | 31.46 | 3.60 |
| PB Ratio | 1.75 | 2.03 |
| P/TBV Ratio | 2.18 | 2.31 |
Enterprise value
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 7.46 | 2.43 |
Income (trailing twelve months)
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $8.67M | $57.94M |
| Gross Profit | $5.74M | $90.47M |
| Operating Income | -$87.91M | -$21.44M |
| Pretax Income | -$90.17M | -$14.45M |
| Net Income | -$90.14M | -$22.46M |
| EBITDA | -$86.24M | -$16.91M |
Margins
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 66.2% | 52.3% |
| Operating Margin | -1014.4% | -44.5% |
| Pretax Margin | -1040.5% | -13.0% |
| Profit Margin | -1040.1% | -39.2% |
| EBITDA Margin | -995.1% | -31.3% |
Returns
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -113.1% | -53.1% |
| Return on Assets (ROA) | -50.3% | -41.0% |
| Return on Capital Employed (ROCE) | -37.6% | -37.8% |
Growth
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 86.0% | 6.01% |
| Revenue Growth (5Y CAGR) | 16.7% | 6.42% |
Balance sheet
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $208.00M | $62.42M |
| Net Cash (Debt) | $208.00M | $15.68M |
| Net Cash Per Share | $2.10 | $0.66 |
| Equity (Book Value) | $155.45M | $48.79M |
| Book Value Per Share | $1.57 | $1.36 |
| Tangible Book Value | $125.00M | $23.06M |
| Working Capital | $199.49M | $75.77M |
Financial position
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 11.30 | 3.30 |
| Quick Ratio | 10.85 | 2.39 |
| Interest Coverage | -10.06 | -7.12 |
Cash flow (trailing twelve months)
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$83.74M | -$12.35M |
Efficiency
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.05 | 0.38 |
| Revenue Per Employee | $192.58K | $398.96K |
| Profits Per Employee | -$2.00M | -$703.34K |
| Employee Count | 45 | 74 |
Dividends and yields
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -33.1% | -22.7% |
Shares
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 99,146,700 | 58,179,650 |
| Shares Change (QoQ) | 1.90% | 0.54% |
| Float | 87,066,500 | 49,173,100 |
| Shares Held by Insiders | 12.2% | 11.6% |
| Shares Held by Institutions | 103.0% | 59.4% |
Taxes
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | -$28.00K | $91.50K |
Scores
| Measure | X4 Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -1.98 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from X4 Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.